Lexaria Bioscience LEXX 深 沪
已收盘 10-23 16:00:00 美东时间
3.08
+0.090
+3.01%
华盛通- 最 高3.1992
- 今 开2.98
- 成交量 2.32万股
- 最 低 2.84
- 昨 收 2.99
- 总市值 648.81万
- 52周最高 21.60
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 2.43
- 委 比 -97.63%
- 总股本 210.65万
- 历史最高 187.50
- 量 比 0.45
- 振 幅 12.01%
- 历史最低 2.84
- 每 手 1
- 风险率 3.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lexaria Bioscience Announces Results From Animal Study GLP-1-A26-1 Evaluating Both DehydraTECH-CBD Compositions And DehydraTECH-Semaglutide; Unfortunately, The DHT-SEMA Concentrations In Brain Tissue Were All At Levels Below The Lower Limit Of Quantitation Of The Bioassay Utilized In This Study
Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the "Study") that evaluated a number of formulation enhancements using both DehydraTECH-CBD ("DHT-CBD") compo...
10-15 21:15
Lexaria Bioscience shares are trading higher after the company announced an update on its financial position, showing cash on hand reaching ~$4.60 per share following $7.9 million in recent net proceeds.
Lexaria Bioscience shares are trading higher after the company announced an update on its financial position, showing cash on hand reaching ~$4.60 per share following $7.9 million in recent net proceeds.
09-18 01:25
Lexaria Bioscience announces $5.9M warrant exercise
Lexaria Bioscience (LEXX) said on Tuesday it agreed to the immediate exercise of warrants for 453,969 shares at $12.92/share, generating approximately $5.9M in gross proceeds. In connection with the e...
09-08 20:18
Lexaria Bioscience Receives Australian R&D Tax Incentive Credit
Lexaria Bioscience ( ($LEXX) ) has provided an update. On August 28, 2026, Lexa...
09-01 22:28
Lexaria Bioscience Announces Australian Tax Office Pays AU$3.667M In Tax Rebate To Co.
Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-ow...
09-01 21:16
Lexaria Bioscience Completes Blood Plasma Pharmacokinetic Bioanalysis Testing In Its 2026 Animal Study 2 Evaluating Oral Delivery Of 2 Next-Generation GLP-Drugs, Amycretin And Retatrutide, In A Total Of 18 Different Study Arms In Dogs Following Use Of Its DehydraTECH Drug Delivery Platform
Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutid...
08-24 21:14
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know
Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd. Here’s what investors need to know. Lexaria Bioscience shares are climbing with conviction. What’s driving LEXX stock higher? Expanding De...
08-14 03:18
Lexaria Bioscience Enters Material Transfer Agreement With Pegbio To Investigate LEXX's DehydraTECH Technology With A Proprietary Pegbio Molecule Under Development For The GLP-1 Industry
Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company. The MTA details the conditions under which PegBio will supply Lexaria with a proprietary GLP-1 molecule which will then be processed with Lexar...
08-13 21:05
Lexaria Bioscience Q3 EPS $(0.08) Beats $(0.09) Estimate
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 0 percent. This is a 61.9 percent increase over losses of $(0.21) per share from the same period last year.
07-14 06:00
Lexaria Bioscience Announces It Began Dosing On June 14 In Its Human Study GLP-1-H26-7 Evaluating Two Oral DehydraTECH-Semaglutide Compositions Against Wegovy
Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo ...
06-25 21:14
